An observational study in Contraception, sponsored by Bayer. Completed at 1 site in Poland. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2011-11-02.
Sponsored by Bayer · Observational
Adherence to the dosing scheme is the principal element of Combined Oral Contraceptives efficiency. On the other hand noncompliance seemed to be an inseparable element of any oral treatment. The aim of the study is to evaluate in everyday practice the relation between dosage errors and indicated factors, potentially influencing the compliance with the dosing scheme.
Bayer is the lead sponsor of 1,643 studies on the registry; 56 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 130 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Gynecological practices patients - starters or current users.
Exclusion Criteria:
Drug: EE/DRSP (Yasmin Product Family)
One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
The percentage of users showing noncompliant behaviors
Time frame: 3 consecutive cycles
The characteristics of noncompliant behavior
Time frame: 3 consecutive cycles
The relation between noncompliant behavior and selected factors
Time frame: 3 consecutive cycles
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.